1. Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019) Authors: Orkin, C.; Porteiro, N.; Berhe, M.; Dretler, R.; Viciana, P.; Tseng, Y.; Oprea, C.; Johnson, M.; Kulagin, V.; Man, C.; Sievers, J.; Currie, A.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Aboud, M.; Smith, K.; Gartland, M.; Steinhart, C. Journal: Journal of infection and public health Issue: Volume 12:Issue 1(2019) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗